Tags

Type your tag names separated by a space and hit enter

Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.
Am J Gastroenterol. 2002 Dec; 97(12):3139-46.AJ

Abstract

OBJECTIVE

The efficacy and tolerability of alosetron in women with diarrhea-predominant irritable bowel syndrome (IBS) have been established in double-blind, placebo-controlled trials. However, the degree to which alosetron fulfills the needs of those suffering from IBS has not been thoroughly examined from the patient's perspective. This randomized, double-blind, placebo-controlled study conducted in women with diarrhea-predominant IBS evaluated patients' overall satisfaction with treatment as well as their satisfaction with respect to several specific medication attributes.

METHODS

Patients randomized to receive either alosetron 1 mg b.id. (n = 532) or placebo (n = 269) were administered a questionnaire on which they rated on 7-point Likert scales their prestudy IBS treatment (at the screening visit) or study medication (on wk 12 or final study visit) with respect to overall satisfaction and 11 specific medication attributes.

RESULTS

Whereas approximately 10% of patients were satisfied or very satisfied overall with prestudy IBS medication, 69% of patients were satisfied or very satisfied overall with alosetron and 46% with placebo (p < 0.001) at the end of 12 wk of therapy. The majority of alosetron-treated patients (61-87%) were satisfied or very satisfied with each of 11 specific medication attributes (p < 0.001 vs placebo for each attribute). Favorable satisfaction ratings for alosetron were assigned to the five medication attributes that patients considered to be most important, including relief of urgency (68% alosetron vs 41% placebo), speed of relief (71% vs 40%), time to return to normal activities (75% vs 49%), relief of abdominal pain (62% vs 44%), and prevention of return of urgency (68% vs 42%).

CONCLUSIONS

Women with diarrhea-predominant IBS are satisfied with alosetron 1 mg b.i.d. treatment overall and also with respect to specific attributes of IBS medication they consider most important.

Authors+Show Affiliations

Mayo Clinic Scottsdale, Scottsdale, Arizona, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12492201

Citation

Olden, Kevin, et al. "Patient Satisfaction With Alosetron for the Treatment of Women With Diarrhea-predominant Irritable Bowel Syndrome." The American Journal of Gastroenterology, vol. 97, no. 12, 2002, pp. 3139-46.
Olden K, DeGarmo RG, Jhingran P, et al. Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol. 2002;97(12):3139-46.
Olden, K., DeGarmo, R. G., Jhingran, P., Bagby, B., Decker, C., Markowitz, M., Carter, E., Bobbitt, W., Dahdul, A., DeCastro, E., Gringeri, L., Johanson, J., Levinson, L., Mula, G., Poleynard, G., Stoltz, R. R., Truesdale, R., & Young, D. (2002). Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. The American Journal of Gastroenterology, 97(12), 3139-46.
Olden K, et al. Patient Satisfaction With Alosetron for the Treatment of Women With Diarrhea-predominant Irritable Bowel Syndrome. Am J Gastroenterol. 2002;97(12):3139-46. PubMed PMID: 12492201.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome. AU - Olden,Kevin, AU - DeGarmo,Ronald G, AU - Jhingran,Priti, AU - Bagby,Barbara, AU - Decker,Chris, AU - Markowitz,Michael, AU - Carter,Eric, AU - Bobbitt,William, AU - Dahdul,Adnan, AU - DeCastro,Enrique, AU - Gringeri,Louis, AU - Johanson,John, AU - Levinson,Lawrence, AU - Mula,Gregory, AU - Poleynard,Gary, AU - Stoltz,Randall R, AU - Truesdale,Richard, AU - Young,Douglas, AU - ,, PY - 2002/12/21/pubmed PY - 2003/1/7/medline PY - 2002/12/21/entrez SP - 3139 EP - 46 JF - The American journal of gastroenterology JO - Am. J. Gastroenterol. VL - 97 IS - 12 N2 - OBJECTIVE: The efficacy and tolerability of alosetron in women with diarrhea-predominant irritable bowel syndrome (IBS) have been established in double-blind, placebo-controlled trials. However, the degree to which alosetron fulfills the needs of those suffering from IBS has not been thoroughly examined from the patient's perspective. This randomized, double-blind, placebo-controlled study conducted in women with diarrhea-predominant IBS evaluated patients' overall satisfaction with treatment as well as their satisfaction with respect to several specific medication attributes. METHODS: Patients randomized to receive either alosetron 1 mg b.id. (n = 532) or placebo (n = 269) were administered a questionnaire on which they rated on 7-point Likert scales their prestudy IBS treatment (at the screening visit) or study medication (on wk 12 or final study visit) with respect to overall satisfaction and 11 specific medication attributes. RESULTS: Whereas approximately 10% of patients were satisfied or very satisfied overall with prestudy IBS medication, 69% of patients were satisfied or very satisfied overall with alosetron and 46% with placebo (p < 0.001) at the end of 12 wk of therapy. The majority of alosetron-treated patients (61-87%) were satisfied or very satisfied with each of 11 specific medication attributes (p < 0.001 vs placebo for each attribute). Favorable satisfaction ratings for alosetron were assigned to the five medication attributes that patients considered to be most important, including relief of urgency (68% alosetron vs 41% placebo), speed of relief (71% vs 40%), time to return to normal activities (75% vs 49%), relief of abdominal pain (62% vs 44%), and prevention of return of urgency (68% vs 42%). CONCLUSIONS: Women with diarrhea-predominant IBS are satisfied with alosetron 1 mg b.i.d. treatment overall and also with respect to specific attributes of IBS medication they consider most important. SN - 0002-9270 UR - https://www.unboundmedicine.com/medline/citation/12492201/Patient_satisfaction_with_alosetron_for_the_treatment_of_women_with_diarrhea_predominant_irritable_bowel_syndrome_ L2 - http://Insights.ovid.com/pubmed?pmid=12492201 DB - PRIME DP - Unbound Medicine ER -